title: Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
abstract: OBJECTIVE
  The objective of this double-blind, placebo-controlled urodynamic pressure/flow study was to assess the efficacy of short-term treatment with the alpha 1-blocker alfuzosin in outflow obstruction of patients with symptomatic benign prostatic hyperplasia (BPH).
  
  
  METHODS
  Urodynamic pressure/flow parameters were assessed after 2 weeks of placebo run-in, 4 weeks of placebo (47 patients) or 2.5 mg t.i.d. alfuzosin treatment (47 patients), followed by an 8-week extension period with alfuzosin (single-blind).
  
  
  CONCLUSIONS
  Four weeks of alfuzosin treatment significantly increased maximum flow (+29.0%) and decreased detrusor pressure at maximum flow (-30.2%), detrusor opening pressure (-39.4%) and maximum detrusor pressure (-28.7%). Short-term alfuzosin treatment improved outflow conditions in BPH by reducing prostatic urethral obstruction.
authors.affiliation: Urology Department, University of Bologna, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Martorana
authors.forename: C
authors.initials: C
authors.lastname: Giberti
authors.forename: F
authors.initials: F
authors.lastname: Di Silverio
authors.forename: M
authors.initials: M
authors.lastname: von Heland
authors.forename: P
authors.initials: P
authors.lastname: Rigatti
authors.forename: R
authors.initials: R
authors.lastname: Colombo
authors.forename: G
authors.initials: G
authors.lastname: Casadei
authors.forename: P
authors.initials: P
authors.lastname: Pacifico
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012212:Rheology; D016037:Single-Blind Method; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy; D014554:Urination / Q000187:drug effects; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin